Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival

Abstract

INTRODUCTIONWhile overexpression of syndecan-1 has been associated with aggressive breast cancer in the Caucasian population, the expression pattern of syndecan-1 in Asian women remains unclear. Triple-positive breast carcinoma, in particular, is a unique subtype that has not been extensively studied. We aimed to evaluate the role of syndecan-1 as a potential biomarker and prognostic factor for triple-positive breast carcinoma in Asian women.METHODS Using immunohistochemistry, staining scores of 61 triple-positive breast carcinoma specimens were correlated with patients' clinicopathological variables such as age, ethnicity, tumour size, histological grade, lymph node status, lymphovascular invasion, associated ductal carcinoma in situ grade, recurrence and overall survival. RESULTS Syndecan-1 had intense staining scores in triple-positive invasive ductal breast carcinomas when compared to normal breast tissue. On multivariate analysis, syndecan-1 epithelial total percentage and immunoreactivity score showed statistical correlation with survival (p = 0.02). CONCLUSIONThe intense staining scores of syndecan-1 and their correlation with overall survival in patients with triplepositive breast carcinoma suggest that syndecan-1 may have a role as a biological and prognostic marker in patients with this specific subtype of breast cancer.

A shift from membranous and stromal syndecan‐1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer

“…The same peritumoral and diffuse patterns of CD138 stroma staining as described in this study had earlier been reported by Stanley et al Either alone or in combination, these stroma patterns occurred in 58.1% of our cancers. This frequency is comparable to the findings of most of the earlier studies, which had described stromal staining in smaller cohorts in the range of 9% to 63% (Table S4). Seven of these eight studies had failed to show a prognostic role of stromal CD138 and one study on 80 patients found a significantly worse prognosis in patients with stromal CD138 staining than in those tumors without.…”

“…[14][15][16][17] Thirteen different studies have analyzed the impact of CD138 expression on BCa prognosis analyzing 37 to 254 cancers by immunohistochemistry and described complex staining patterns including membranous, cytoplasmic, and stromal staining. [18][19][20][21][22] The conclusions from these studies were highly controversial, however, the authors described both increased, 17,23,24 and decreased 25 CD138 expression in BCa as compared to normal breast epithelium and reported associations of high CD138 expression with possibly favorable 25 and unfavorable, 17,20,23 prognosis.…”

Extracellular Matrix–receptor Interaction Signaling Genes Associated with Inferior Breast Cancer Survival

“…Our results revealed that SDC1 might play an oncogenic role in regulating breast cancer progression. Previous studies have reported similar results that SDC1 was significantly upregulated in breast cancer and that high SDC1 expression was correlated with poor prognostic value for breast cancer (31,34,35). Nguyen et al reported that high SDC1 expression was significantly associated with a higher histological grade and had a negative effect on both OS and disease-free survival for patients with breast cancer (35).…”

Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues

“…It is probably because of this that the existing literature is highly discrepant with respect to the prevalence of CD138 expression in different tumor types. For example, the range of the reported CD138 positivity ranges from 26% [10] to 100% [11] in urinary bladder cancer, from 23% [10] to 89% [12] in squamous lung cancer, from 33% [13] to 100% [14] in breast cancer, from 50.5% [15] to 87% [10] in squamous cell carcinoma of the esophagus, and from 24.7% [16] to 89.7% [17] in squamous cell carcinoma of the cervix.…”